(June 2020) TrialSiteNews Clinical Trials: Malone vs Callahan / Inovio / Famotidine may help CV19

Downloaded form : https://www.youtube.com/watch?v=Mvqf9FgV_YI
Download date : May 26, 2023
Title : Clinical Trials and Research News Weekly Roundup | S2 E25 | Famotidine May Address COVID-19

TrialSite News

As of June 29 2023 : 8,799 views Jun 22, 2020 #COVID19 #Famotidine
#Famotidine Leads to Improved #COVID19 Patient Outcomes based on Retrospective Case Series Led by Cold Spring Harbor Laboratory:
A group of prominent New York-based physicians and scientists led by Cold Spring Harbor Laboratory, Northwell Health Cancer institute conducted a retrospective case series targeting ten (10) non-hospitalized patients with SARS-CoV-2, the virus behind the COVID-19 pandemic. It has been alleged that the over-the-counter histamine-2 receptor antagonist called Famotidine could possibly address the novel coronavirus. This insight originally derived from the analysis of Dr. Robert Malone and team associated with the U.S. government research contracts as well as observations of a prominent physician and research named Dr. Michael Callahan after his analysis of over 6,000 patient records at the Wuhan pandemic epicenter. After monitoring and quantitatively analyzing the longitudinal changes in patient reported outcome measures of patients who had been self-administering high-doses of Famotidine orally, the Cold Spring Harbor Laboratory and Northwell Health investigational team found that not only are high doses well tolerated but they are associated with improved patient-reported outcomes in non-hospitalized patients with COVID-19. Meanwhile, a large study at Northwell has commenced in April, including both hydroxychloroquine and Famotidine but there is uncertainty with the use of the anti-malarial drug moving forward.

#INOVIOPharmaceuticals & Korean Government Close Deal: INO-4800 Phase I/II Trial to Commence in Korea Late June:
INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to commence a Phase I/II clinical trial of INO-4800, INOVIO’s COVID-19 vaccine candidate. A formal signing ceremony occurred involving of key principals for this important event in Korea. The clinical trials will start later in June.